LENZ Therapeutics Provides Phase 3 Timing Guidance
LENZ Therapeutics provided Phase 3 timing and formulation guidance at the Academy and Eyecelerator meetings in November.
LENZ shared they expect to start their pivotal Phase 3 trial in 2Q 2022. This trial will include 2 eye drop formulations for presbyopia.
- Optimal concentration for a pinhole effect
- Minimal concern of induced myopia
1.75% Aceclidine + Brimonidine
- Potential for increased duration
- Added benefit of eye whitening